If You Invested in AVAI BIO INC (AVAI)

Avant Technologies Inc. (OTCQB: AVAI) is a Nevada-based corporation that describes itself as an emerging biotechnology and technology company. According to the company’s public communications, Avant focuses on advancing health through strategic biotech partnerships and on developing healthcare solutions that use artificial intelligence and biotechnologies. Its activities center on cell-based therapies for chronic and age-related diseases, as well as AI-driven tools for early disease detection.

Avant has stated that it is emphasizing a partnership-driven model built around joint ventures and licensing agreements. Rather than developing every asset internally, the company seeks out genetically modified cell lines and related technologies from specialized partners and works with them to research, develop, and potentially commercialize new therapies. Areas of focus mentioned in its press releases include diabetes, anti-aging and longevity, Alzheimer’s disease, heart disease, cancer, kidney disease, and other age-related conditions.

Biotech Focus: Cell-Based Therapies and Genetically Modified Cells

In multiple announcements, Avant describes itself as an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders. The company highlights work with genetically modified human cells that are engineered to perform specific functions in the body, such as producing insulin or secreting the protein α-Klotho. These efforts are pursued primarily through joint ventures with established biotechnology firms that contribute proprietary technologies and know-how.

Avant’s strategy includes identifying genetically modified cell lines and, through joint venture and licensing agreements, working to develop cell-based therapies. The company’s public statements emphasize the potential to address chronic and age-related diseases and to promote longevity by restoring or supplementing biological functions that may be deficient in patients.

Joint Ventures in Diabetes and Cell Encapsulation

According to a Form 8-K filed with the U.S. Securities and Exchange Commission and accompanying press releases, Avant entered into a Joint Venture and License Agreement with SGAustria Pte. Ltd., a Singapore-based biotechnology company. The agreement provides for the formation of a new joint venture company called Insulinova, Inc. Insulinova is intended to focus on developing diabetes treatments that combine stem cells and/or other cells with encapsulation technologies.

SGAustria is described as a biotechnology company specializing in clinically proven cell encapsulation, GMP-grade cell products, and cell line development, supported by more than 50 peer-reviewed publications and contracts with pharmaceutical and biotech companies. Its proprietary Cell-in-a-Box® encapsulation technology is designed to protect living cells while allowing the exchange of nutrients and therapeutic molecules. Avant’s public disclosures state that Insulinova will pursue research and development of therapies for type 1 and some insulin-dependent type 2 diabetes, using genetically modified cells that produce, store, and secrete insulin, in combination with encapsulation to protect these cells from immune rejection.

Under the 8-K, Avant agreed to contribute resources and capital required for Insulinova’s formation and initial operations in exchange for common stock, with ownership of Insulinova to be split 50/50 between Avant and SGAustria. The filing notes that Avant will also use its efforts to help arrange additional funding as described in the agreement.

Klotho-Based Therapies and the Klothonova Joint Venture

Avant has also disclosed a Joint Venture and License Agreement with SGAustria/Austrianova to form Klothonova Inc., a Nevada-based entity equally owned by Avant and an Austrianova affiliate. According to the company’s press releases and Form 8-K, Klothonova is focused on developing cell-based therapies that utilize the protein Klotho, sometimes described in scientific literature as a “longevity protein.”

Klothonova’s program aims to engineer genetically modified human cells that overexpress Klotho and then encapsulate these cells using Austrianova’s Cell-in-a-Box® technology. Avant reports that proof-of-concept studies have generated encapsulated human cells that over-produce Klotho and continue to secrete the protein after encapsulation. The joint venture’s stated goals include advancing these Klotho-producing cell lines through preclinical work and, ultimately, clinical studies for age-related conditions such as Alzheimer’s disease, heart disease, cancer, kidney disease, and other disorders associated with aging and Klotho deficiency.

Avant’s disclosures state that Klothonova will operate as a 50/50 joint venture, with Avant contributing capital and other resources and Austrianova contributing its encapsulation technology, cell biology expertise, and related intellectual property and know-how. The company has indicated that Austrianova operates ISO9001:2015-compliant GMP facilities and that preparations are underway to support clinical-grade production of Klotho-producing cell lines.

AI-Driven Healthcare and the Ainnova Partnership

In addition to its biotech collaborations, Avant describes itself as an emerging technology company developing solutions in healthcare using artificial intelligence. Through a joint venture with Ainnova Tech, Inc., a healthcare technology company, Avant participates in the development and planned clinical evaluation of Vision AI, an artificial intelligence platform for the early detection of diabetic retinopathy.

Company press releases explain that a joint venture entity, Ai-nova Acquisition Corp. (AAC), was formed by Avant and Ainnova to advance and commercialize Ainnova’s technology portfolio. AAC holds worldwide licensing rights to Ainnova’s technologies, including rights in the United States. Avant has reported that Ainnova, working with a contract research organization, is refining clinical trial protocols and patient recruitment strategies for a planned FDA-regulated clinical study of Vision AI in diabetic retinopathy.

According to these announcements, the planned clinical study is expected to enroll a multiethnic population of patients with diabetes at community clinics and primary care facilities, with the goal of generating real-world data to support a future FDA 510(k) submission. Avant’s role, as described in its communications, is to collaborate through the joint venture structure and support the advancement and potential commercialization of AI-based healthcare technologies.

Partnership-Driven Business Model

Avant’s public statements emphasize a partnership-driven business model that relies on joint ventures and licensing agreements with other biotechnology and health technology companies. The company highlights that this approach allows it to identify promising cell lines and technologies globally and work with specialized partners, scientists, and clinicians. By doing so, Avant aims to share development responsibilities and risks while contributing capital, strategic direction, and access to markets through its joint venture entities.

In a press release describing a “pivotal evolution” in its business direction, Avant notes that it is prioritizing collaborations with companies that specialize in genetically modified cell lines and with a global cell-encapsulation technology firm. The company also references a joint venture with Ainnova Tech that integrates AI-based diagnostics with its broader focus on chronic and age-related diseases.

Corporate Identity and Name Change Application

Avant Technologies Inc. is incorporated in Nevada. In a Form 8-K filed with the SEC, the company reported that it filed an application with the Financial Industry Regulatory Authority (FINRA) to change its corporate name from Avant Technologies Inc. to Avaí Bio, Inc. The filing states that this proposed name change is intended to better reflect the company’s current business, which centers on biotechnology and related health-focused technologies. The same filing notes that the company’s ticker symbol, AVAI, would remain in place until FINRA declares the corporate action effective and assigns any new trading symbol, if applicable.

These disclosures indicate an effort by the company to align its corporate identity more closely with its stated emphasis on biotechnology, cell-based therapies, and longevity-focused programs.

Retraction of Prior Announcement

Avant has also issued a press release retracting an earlier announcement regarding a purported joint venture and license agreement with Art-Islets Pte. Ltd. and Austrianova. In the retraction, the company states that no binding joint venture or license agreement among Avant, Art-Islets, and Austrianova had been executed at that time, and it advises that any descriptions of collaborative activities, technology contributions, or anticipated clinical milestones in the retracted release should not be relied upon. This clarification provides context on which partnerships are formally documented and which are not.

Summary of Key Focus Areas

Based on its public disclosures and SEC filings, Avant’s main areas of focus include:

• Cell-based therapies for diabetes through Insulinova, Inc., using genetically modified insulin-producing cells combined with encapsulation technologies.
• Klotho-based cell therapies through Klothonova Inc., aimed at age-related diseases and longevity by overexpressing and delivering the Klotho protein via encapsulated cells.
• AI-driven diagnostics through its joint venture with Ainnova Tech, particularly the Vision AI platform for early detection of diabetic retinopathy.
• Strategic biotech partnerships that rely on joint ventures and licensing agreements to identify and develop genetically modified cell lines and related technologies.

Avant’s disclosures consistently describe the company as emerging and partnership-focused, with an emphasis on chronic and age-related conditions, regenerative medicine concepts, and the integration of cell-based and AI-based approaches in healthcare.